Advances In Castration-resistant Prostate Cancer

Prostate cancer(prostate cancer, PCa),the most common malignancy in men,is the disorder of male reproductive system and a common malignancy that affect men’s life.Epidemiological studies indicate: incidence of PCa in worldwide has a clear upward trend, but there are big differences in different regions, Europe and North America,the highest incidence of 150/10 million, while other regions minimum of 1/10 million.The incidence rate of PCa in our country has continued to rise in recent years,because of the following:with the extension of our population proportion of life, more and more elderly malelarger, dietary habits and lifestyle changes, especially pays more attention to the disease,the diagnosis and treatment level of improvement.However,the majority of the PCa patients in our country be diagnosed relatively lag because prostate cancer early symptoms are not obvious and screening. The majority of patients after androgen deprivation therapy(androgen deprivation therapy, ADT),gradually transformed into castration-resistant prostate cancer(castration resistant prostate cancer, CRPC), then there Metastatic tumor, eventually leading to ineffective treatments. There are no effective treatment strategy for CRPC patients system at this stag, for which experts are still made unremitting efforts. Currently, there are a variety of new drugs for patients with CRPC listed or approved for clinical application, such as: abiraterone(TAK-700), cabazitaxel, MDV3100, denosumab and so on. In addition there are a variety of drugs, such as Ixabepilone, lpilimumab is currently in clinical trials.Through to experts study of CRPC, mainly PCa medication, Author will reviewe the newprogress of CRPC diagnosis and treatment,to guiding clinical therapy and a better service to patients.